https://mararating.com/evidence-quality-robustness-why-trustworthy-data-wins-the-day/ 2025-11-26T12:52:50+00:00 daily 0.8 https://mararating.com/ 2025-12-02T14:52:00+00:00 daily 1.0 https://mararating.com/about/ 2025-11-25T14:38:00+00:00 daily 0.8 https://mararating.com/services/ 2025-11-25T14:41:16+00:00 daily 0.8 https://mararating.com/mara-ratings-list/ 2025-11-25T14:40:25+00:00 daily 0.8 https://mararating.com/methodology/ 2025-11-25T14:40:36+00:00 daily 0.8 https://mararating.com/pharma-leaders-u-s-coverage-is-earned-not-assumed/ 2025-11-25T14:10:29+00:00 daily 0.8 https://mararating.com/mara-rating-in-the-workflow-how-market-access-bd-teams-use-it/ 2025-11-25T14:19:36+00:00 daily 0.8 https://mararating.com/brensocatib-first-in-class-for-ncfb-but-will-patients-see-it/ 2025-11-25T14:26:40+00:00 daily 0.8 https://mararating.com/drug-developers-the-definitive-hta-checklist/ 2025-11-27T11:33:50+00:00 daily 0.8 https://mararating.com/making-uncertainty-work-for-you-in-hta/ 2025-11-25T14:04:01+00:00 daily 0.8 https://mararating.com/what-is-market-access-conclusions-and-appendices/ 2025-11-27T14:35:56+00:00 daily 0.8 https://mararating.com/donanemab-mara-market-access-rating-for-alzheimers-disease/ 2025-11-27T14:20:48+00:00 daily 0.8 https://mararating.com/report/filgrastim-for-the-treatment-of-severe-chronic-neutropenia-as-of-august-2025/ 2025-11-27T13:23:53+00:00 daily 0.8 https://mararating.com/report/bivigam-for-primary-humoral-immunodeficiency-as-of-august-2025/ 2025-11-27T13:23:54+00:00 daily 0.8 https://mararating.com/report/ensifentrine-for-maintenance-treatment-of-chronic-obstructive-pulmonary-disease-copd-as-of-july-2025/ 2025-11-27T13:23:55+00:00 daily 0.8 https://mararating.com/report/deucrictibant-for-on-demand-treatment-of-hae-attacks-as-of-september-2025/ 2025-11-27T13:23:56+00:00 daily 0.8 https://mararating.com/report/baxdrostat-for-treating-uncontrolled-and-resistant-hypertension-as-of-september-2025/ 2025-11-27T13:23:57+00:00 daily 0.8 https://mararating.com/report/tolebrutinib-for-treating-non-relapsing-secondary-progressive-multiple-sclerosis-as-of-august-2025/ 2025-11-27T13:23:59+00:00 daily 0.8 https://mararating.com/operating-model-governance-ways-of-working/ 2025-11-27T14:32:39+00:00 daily 0.8 https://mararating.com/evidence-methods-playbook-for-non-technical-leaders/ 2025-11-27T13:59:22+00:00 daily 0.8 https://mararating.com/global-market-access-models-and-therapeutic-area-archetypes/ 2025-11-27T14:12:42+00:00 daily 0.8 https://mararating.com/market-access-across-the-development-pathway-and-the-stakeholders/ 2025-11-25T14:01:45+00:00 daily 0.8 https://mararating.com/market-access-in-pharmaceuticals-a-white-paper/ 2025-11-25T13:53:18+00:00 daily 0.8 https://mararating.com/how-mara-ratings-can-flag-slow-u-s-uptake-before-launch/ 2025-11-25T14:09:49+00:00 daily 0.8 https://mararating.com/resource-use-cost-implications-balancing-affordability-impact/ 2025-11-25T14:13:28+00:00 daily 0.8 https://mararating.com/care-pathway-integration-fitting-seamlessly-into-practice/ 2025-11-25T14:14:49+00:00 daily 0.8 https://mararating.com/patient-population-who-counts-matters/ 2025-11-25T14:16:15+00:00 daily 0.8 https://mararating.com/lecanemab-early-alzheimers-disease/ 2025-11-27T14:17:37+00:00 daily 0.8 https://mararating.com/comparator-selection-your-evidences-true-benchmark/ 2025-11-25T14:22:20+00:00 daily 0.8 https://mararating.com/aficamten-hypertrophic-cardiomyopathy/ 2025-11-27T14:23:40+00:00 daily 0.8 https://mararating.com/health-related-quality-of-life-how-patient-experience-influence/ 2025-11-25T14:27:15+00:00 daily 0.8 https://mararating.com/datopotamab-deruxtecan-for-breast-cancer/ 2025-11-27T14:33:22+00:00 daily 0.8 https://mararating.com/every-payers-checklist-is-different-safety-tolerability/ 2025-11-25T14:28:02+00:00 daily 0.8 https://mararating.com/with-high%e2%80%91potency-obesity-therapies-poised-to-reshape-care/ 2025-11-25T14:31:34+00:00 daily 0.8 https://mararating.com/ensifentrine-mara-market-access-rating-2025-for-copd/ 2025-11-27T11:42:44+00:00 daily 0.8 https://mararating.com/venture-investors-acquirers-your-definitive-pr-checklist/ 2025-11-27T11:50:53+00:00 daily 0.8 https://mararating.com/mara-rating-our-reason-to-exist/ 2025-11-25T14:36:39+00:00 daily 0.8 https://mararating.com/mara-rating-b-spots-access-risks-in-mercks-10-b-verona-deal/ 2025-11-27T13:21:47+00:00 daily 0.8 https://mararating.com/clinical-effectiveness-what-truly-moves-the-needle/ 2025-11-25T14:35:01+00:00 daily 0.8 https://mararating.com/the-definitive-ma-checklist-for-market-access-professionals/ 2025-11-27T13:06:41+00:00 daily 0.8 https://mararating.com/the-cost-effectiveness-dimension-in-mara-rating-methodology/ 2025-11-25T14:32:57+00:00 daily 0.8 https://mararating.com/breaking-the-bias-why-market-access-teams-must-avoid-think-traps/ 2025-11-25T14:32:22+00:00 daily 0.8 https://mararating.com/suzetrigine-neuropathic-pain/ 2025-11-27T13:36:43+00:00 daily 0.8 https://mararating.com/nipocalimab-generalized-myasthenia-gravis/ 2025-11-27T13:30:29+00:00 daily 0.8 https://mararating.com/orforglipron-obesity-type-2-diabetes/ 2025-11-27T11:07:13+00:00 daily 0.8 https://mararating.com/retatrutide-obesity-metabolic-disorders/ 2025-11-27T10:46:20+00:00 daily 0.8 https://mararating.com/survodutide-obesity-treatment/ 2025-11-27T10:18:03+00:00 daily 0.8 https://mararating.com/tolebrutinib-secondary-progressive-ms/ 2025-11-27T10:11:01+00:00 daily 0.8 https://mararating.com/cagrilintide-semaglutide-obesity-type-2-diabetes/ 2025-11-27T10:04:33+00:00 daily 0.8 https://mararating.com/brensocatib-for-non-cystic-fibrosis-bronchiectasis/ 2025-11-27T11:22:21+00:00 daily 0.8 https://mararating.com/corrections-and-takedown-policy/ 2025-11-25T14:39:59+00:00 daily 0.8 https://mararating.com/personal-data-policy/ 2025-11-25T14:41:03+00:00 daily 0.8 https://mararating.com/compliance/ 2025-11-25T14:38:20+00:00 daily 0.8 https://mararating.com/report/abaloparatide-for-treating-osteoporosis-after-menopause-as-of-august-2024/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/abemaciclib-for-treating-hormone-receptor-positive-her2-negative-advanced-breast-cancer-after-endocrine-therapy-as-of-september-2021/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/abemaciclib-for-adjuvant-treatment-of-hormone-receptor-positive-her2-negative-node-positive-early-breast-cancer-at-high-risk-of-recurrence-as-of-july-2022/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/abiraterone-for-treating-newly-diagnosed-high-risk-hormone-sensitive-metastatic-prostate-cancer-as-of-august-2021/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/abrocitinib-for-treating-moderate-to-severe-atopic-dermatitis-as-of-august-2022/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/acalabrutinib-for-treating-chronic-lymphocytic-leukaemia-as-of-april-2021/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/alectinib-for-adjuvant-treatment-of-alk-positive-non-small-cell-lung-cancer-as-of-november-2024/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/alemtuzumab-for-treating-highly-active-relapsing-remitting-multiple-sclerosis-as-of-may-2024/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/alpelisib-for-treating-hormone-receptor-positive-her2-negative-pik3ca-mutated-advanced-breast-cancer-as-of-august-2022/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/amivantamab-for-treating-egfr-exon-20-insertion-mutation-positive-advanced-non-small-cell-lung-cancer-after-platinumbased-chemotherapy-as-of-december-2022/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/anakinra-for-treating-stills-disease-as-of-march-2021/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/survodutide-for-obesity-treatment-as-of-july-2025/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/retatrutide-for-obesity-%c2%b1-metabolic-disorders-as-of-july-2025/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/orforglipron-for-obesity-and-type-2-diabetes-as-of-july-2025/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/cagrilintide-for-treating-obesity-with-or-without-type-2-diabetes-as-of-july-2025/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/anhydrous-for-preventing-hearing-loss-caused-by-cisplatin-chemotherapy-in-people-1-month-to-17-years-with-localised-solid-tumours-as-of-january-2025/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/apalutamide-for-treating-high-risk-hormone-relapsed-nonmetastatic-prostate-cancer-as-of-october-2021/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/apalutamide-for-treating-hormone-sensitive-metastatic-prostate-cancer-as-of-october-2021/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-non-valvular-atrial-fibrillation-as-of-july-2021/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/asciminib-for-treating-chronic-myeloid-leukaemia-after-2-or-more-tyrosine-kinase-inhibitors-as-of-august-2022/ 2025-11-27T13:22:06+00:00 daily 0.8 https://mararating.com/report/atezolizumab-for-untreated-extensive-stage-small-cell-lung-cancer-as-of-july-2020/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/atezolizumab-for-treating-triple-negative-unresectable-locally-advanced-or-metastatic-breast-cancer-as-of-july-2020/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/atezolizumab-for-treating-advanced-or-unresectable-hepatocellular-carcinoma-as-of-december-2020/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/atezolizumab-for-untreated-metastatic-non-small-cell-lung-cancer-nsclc-as-of-june-2021/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/atezolizumab-for-untreated-pd-l1-positive-advanced-urothelial-cancer-when-cisplatin-is-unsuitable-as-of-october-2021/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/atezolizumab-for-adjuvant-treatment-of-resected-non-small-cell-lung-cancer-as-of-september-2022/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/atogepant-for-preventing-migraine-as-of-may-2024/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avacopan-for-treating-severe-active-granulomatosis-with-polyangiitis-or-microscopic-polyangiitis-as-of-september-2022/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avalglucosidase-for-treating-pompe-disease-as-of-august-2022/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avapritinib-for-treating-advanced-systemic-mastocytosis-as-of-november-2024/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avatrombopag-for-treating-thrombocytopenia-in-people-with-chronic-liver-disease-needing-a-planned-invasive-procedure-as-of-june-2020/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avatrombopag-for-treating-primary-chronic-immune-thrombocytopenia-as-of-december-2022/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avelumab-for-treating-metastatic-merkel-cell-carcinoma-as-of-april-2021/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avelumab-for-untreated-advanced-renal-cell-carcinoma-in-adults-as-of-september-2020/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avelumab-for-untreated-metastatic-merkel-cell-carcinoma-as-of-april-2021/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/avelumab-for-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-cancer-after-platinum-based-chemotherapy-as-of-may-2022/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/axicabtagene-for-treating-diffuse-large-b-cell-lymphoma-and-primary-mediastinal-large-b-cell-lymphoma-after-2-or-more-systemic-therapies-as-of-february-2023/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/axicabtagene-for-treating-relapsed-or-refractory-follicular-lymphoma-after-3-or-more-systemic-treatments-as-of-june-2023/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/axicabtagene-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-first-line-chemoimmunotherapy-as-of-june-2023/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/baricitinib-for-treating-moderate-to-severe-atopic-dermatitis-as-of-march-2021/ 2025-11-27T13:22:11+00:00 daily 0.8 https://mararating.com/report/baricitinib-for-treating-severe-alopecia-areata-as-of-october-2023/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/belimumab-for-treating-active-autoantibody-positive-systemic-lupus-erythematosus-as-of-december-2021/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/belumosudil-for-treating-chronic-graft-versus-host-disease-after-2-or-more-systemic-treatments-in-people-12-years-and-over-as-of-february-2024/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/belzutifan-for-treating-tumours-associated-with-von-hippel-lindau-disease-as-of-october-2024/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/bempedoic-for-treating-primary-hypercholesterolaemia-or-mixed-dyslipidaemia-as-of-april-2021/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/berotralstat-for-preventing-recurrent-attacks-of-hereditary-angioedema-as-of-october-2021/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/bevacizumab-for-treating-wet-age-related-macular-degeneration-as-of-december-2024/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/bimekizumab-for-treating-moderate-to-severe-plaque-psoriasis-as-of-september-2021/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/bimekizumab-for-treating-active-psoriatic-arthritis-as-of-october-2023/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/bimekizumab-for-treating-axial-spondyloarthritis-as-of-october-2023/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/blinatumomab-for-consolidation-treatment-of-philadelphia-chromosome-negative-cd19-positive-minimal-residual-disease-negative-b-cell-precursor-acute-lymphoblastic-leukaemia-as-of-march-2025/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/brentuximab-for-untreated-systemic-anaplastic-large-cell-lymphoma-as-of-august-2020/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/brentuximab-for-untreated-stage-3-or-4-cd30-positive-hodgkin-lymphoma-as-of-may-2025/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/brexucabtagene-for-treating-relapsed-or-refractory-mantle-cell-lymphoma-as-of-february-2021/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/brexucabtagene-for-treating-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukaemia-in-people-26-years-and-over-as-of-june-2023/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/brigatinib-for-treating-alk-positive-advanced-non-small-cell-lung-cancer-that-has-not-been-previously-treated-with-an-alk-inhibitor-as-of-january-2021/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/brolucizumab-for-treating-wet-age-related-macular-degeneration-as-of-february-2021/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/brolucizumab-for-treating-visual-impairment-due-to-diabetic-macular-oedema-as-of-august-2022/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/budesonide-for-inducing-remission-of-eosinophilic-oesophagitis-as-of-june-2021/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/bulevirtide-for-treating-chronic-hepatitis-d-as-of-june-2023/ 2025-11-27T13:22:17+00:00 daily 0.8 https://mararating.com/report/burosumab-for-treating-x-linked-hypophosphataemia-in-adults-as-of-august-2024/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cabotegravir-for-treating-hiv-1-infection-as-of-january-2022/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cabozantinib-for-treating-advanced-hepatocellular-carcinoma-hcc-in-adults-who-have-previously-been-treated-with-sorafenib-as-of-december-2022/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cabozantinib-for-previously-treated-advanced-differentiated-thyroid-cancer-unsuitable-for-or-refractory-to-radioactive-iodine-as-of-november-2023/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cabozantinib-for-untreated-advanced-renal-cell-carcinoma-as-of-april-2024/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cannabidiol-for-treating-seizures-caused-by-tuberous-sclerosis-complex-as-of-march-2023/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/capivasertib-for-treating-hormone-receptor-positive-her2-negative-advanced-breast-cancer-after-endocrine-treatment-as-of-may-2025/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/caplacizumab-for-treating-acute-acquired-thrombotic-thrombocytopenic-purpura-as-of-december-2020/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/carfilzomib-for-treating-multiple-myeloma-as-of-november-2020/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/carfilzomib-for-treating-multiple-myeloma-in-adults-who-have-had-only-1-previous-therapy-which-included-bortezomib-as-of-april-2021/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cemiplimab-for-treating-advanced-cutaneous-squamous-cell-carcinoma-as-of-june-2022/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cenobamate-for-treating-focal-onset-seizures-in-epilepsy-as-of-may-2025/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/chlormethine-for-treating-mycosis-fungoides-type-cutaneous-t-cell-lymphoma-as-of-august-2021/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cipaglucosidase-for-treating-late-onset-pompe-disease-as-of-august-2023/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cladribine-for-treating-relapsing-remitting-multiple-sclerosis-as-of-may-2024/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/cladribine-for-treating-active-relapsing-forms-of-multiple-sclerosis-as-of-april-2025/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/crizotinib-for-treating-ros1-positive-advanced-non-small-cell-lung-cancer-as-of-december-2024/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/crovalimab-for-treating-paroxysmal-nocturnal-haemoglobinuria-in-people-12-years-and-over-as-of-november-2024/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/dabigatran-for-the-prevention-of-stroke-and-systemic-embolism-in-atrial-fibrillation-as-of-july-2021/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/dabrafenib-for-treating-braf-v600-mutation-positive-advanced-non-small-cell-lung-cancer-as-of-june-2023/ 2025-11-27T13:22:23+00:00 daily 0.8 https://mararating.com/report/dabrafenib-for-treating-braf-v600e-mutation-positive-glioma-in-children-and-young-people-aged-1-year-and-over-as-of-may-2024/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/danicopan-for-treating-paroxysmal-nocturnal-haemoglobinuria-as-of-october-2024/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/dapagliflozin-for-treating-chronic-heart-failure-with-reduced-ejection-fraction-as-of-february-2021/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/dapagliflozin-for-treating-chronic-kidney-disease-ckd-as-of-march-2022/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/dapagliflozin-for-treating-chronic-heart-failure-with-preserved-or-mildly-reduced-ejection-fraction-as-of-june-2023/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/daratumumab-for-untreated-multiple-myeloma-when-a-stem-cell-transplant-is-suitable-as-of-february-2022/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/daratumumab-for-treating-relapsed-and-refractory-multiple-myeloma-as-of-april-2022/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/daratumumab-for-treating-multiple-myeloma-in-adults-who-have-had-just-1-previous-line-of-treatment-as-of-june-2023/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/daratumumab-for-untreated-multiple-myeloma-when-a-stem-cell-transplant-is-unsuitable-as-of-october-2023/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/daratumumab-for-treating-newly-diagnosed-systemic-amyloid-light-chain-amyloidosis-as-of-march-2024/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/daridorexant-for-treating-long-term-insomnia-as-of-october-2023/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/darolutamide-for-treating-hormone-relapsed-nonmetastatic-prostate-cancer-as-of-november-2020/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/darolutamide-for-treating-hormone-sensitive-metastatic-prostate-cancer-as-of-june-2023/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/deucravacitinib-for-treating-moderate-to-severe-plaque-psoriasis-as-of-june-2023/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/deucrictibant-for-prophylaxis-for-hereditary-angioedema-as-of-june-2025/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/dexamethasone-for-treating-diabetic-macular-oedema-as-of-september-2022/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/difelikefalin-for-treating-pruritus-in-people-having-haemodialysis-as-of-may-2023/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/diroximel-for-treating-relapsing-remitting-multiple-sclerosis-as-of-june-2022/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/dostarlimab-for-treating-advanced-or-recurrent-endometrial-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency-as-of-march-2022/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/dostarlimab-for-treating-primary-advanced-or-recurrent-endometrial-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency-as-of-may-2025/ 2025-11-27T13:22:28+00:00 daily 0.8 https://mararating.com/report/dupilumab-for-treating-severe-asthma-with-type-2-inflammation-as-of-december-2021/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/dupilumab-for-treating-moderate-to-severe-prurigo-nodularis-as-of-march-2024/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/durvalumab-for-maintenance-treatment-of-unresectable-non-small-cell-lung-cancer-after-platinum-based-chemoradiation-as-of-june-2022/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/durvalumab-for-treating-unresectable-or-advanced-biliary-tract-cancer-as-of-january-2024/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/durvalumab-for-treating-resectable-non-small-cell-lung-cancer-as-of-january-2025/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/durvalumab-for-untreated-extensive-stage-small-cell-lung-cancer-as-of-february-2025/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/edoxaban-for-preventing-stroke-and-systemic-embolism-in-people-with-non-valvular-atrial-fibrillation-as-of-july-2021/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/efanesoctocog-for-treating-and-preventing-bleeding-episodes-in-haemophilia-a-in-people-2-years-and-over-as-of-april-2025/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/elacestrant-for-treating-oestrogen-receptor-positive-her2-negative-advanced-breast-cancer-with-an-esr1-mutation-after-endocrine-treatment-as-of-february-2025/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/elafibranor-for-treating-primary-biliary-cholangitis-in-adults-as-of-november-2024/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/elranatamab-for-treating-relapsed-and-refractory-multiple-myeloma-after-3-or-more-treatments-as-of-december-2024/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/empagliflozin-for-treating-chronic-heart-failure-with-reduced-ejection-fraction-as-of-march-2022/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/empagliflozin-for-treating-chronic-heart-failure-with-preserved-or-mildly-reduced-ejection-fraction-as-of-november-2023/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/empagliflozin-for-treating-chronic-kidney-disease-ckd-as-of-december-2023/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/encorafenib-for-treating-braf-v600e-mutation-positive-metastatic-colorectal-cancer-as-of-january-2021/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/entrectinib-for-treating-ros1-positive-advanced-non-small-cell-lung-cancer-as-of-august-2020/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/entrectinib-for-treating-ntrk-fusion-positive-solid-tumours-as-of-august-2020/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/enzalutamide-for-treating-hormone-sensitive-metastatic-prostate-cancer-as-of-july-2021/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/epcoritamab-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-2-or-more-systemic-treatments-as-of-march-2024/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/eplontersen-for-treating-hereditary-transthyretin-related-amyloidosis-as-of-november-2024/ 2025-11-27T13:22:35+00:00 daily 0.8 https://mararating.com/report/eptinezumab-for-preventing-migraine-as-of-march-2023/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/erdafitinib-for-treating-unresectable-or-metastatic-urothelial-cancer-with-fgfr3-alterations-after-a-pd-1-or-pd-l1-inhibitor-as-of-may-2025/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/erenumab-for-preventing-migraine-as-of-march-2021/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/esketamine-for-treatment-resistant-depression-as-of-december-2022/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/etranacogene-for-treating-moderately-severe-or-severe-haemophilia-b-as-of-july-2024/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/etrasimod-for-treating-moderately-to-severely-active-ulcerative-colitis-in-people-aged-16-and-over-as-of-march-2024/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/evinacumab-for-treating-homozygous-familial-hypercholesterolaemia-in-people-12-years-and-over-as-of-september-2024/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/exagamglogene-for-treating-transfusion-dependent-beta-thalassaemia-in-people-12-years-and-over-as-of-september-2024/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/exagamglogene-for-treating-severe-sickle-cell-disease-in-people-12-years-and-over-as-of-february-2025/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/faricimab-for-treating-diabetic-macular-oedema-as-of-june-2022/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/faricimab-for-treating-wet-age-related-macular-degeneration-as-of-june-2022/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/faricimab-for-treating-visual-impairment-caused-by-macular-oedema-after-retinal-vein-occlusion-as-of-september-2024/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/fedratinib-for-treating-disease-related-splenomegaly-or-symptoms-in-myelofibrosis-as-of-november-2024/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/fenfluramine-for-treating-seizures-associated-with-dravet-syndrome-as-of-july-2022/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/fenfluramine-for-treating-seizures-associated-with-lennox-gastaut-syndrome-in-people-2-years-and-over-as-of-march-2025/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/filgotinib-for-treating-moderate-to-severe-rheumatoid-arthritis-as-of-february-2021/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/filgotinib-for-treating-moderately-to-severely-active-ulcerative-colitis-as-of-june-2022/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/finerenone-for-treating-chronic-kidney-disease-in-type-2-diabetes-as-of-march-2023/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/fluocinolone-for-treating-chronic-diabetic-macular-oedema-as-of-march-2024/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/foslevodopafoscarbidopa-for-treating-advanced-levodopa-responsive-parkinsons-with-motor-symptoms-as-of-november-2023/ 2025-11-27T13:22:41+00:00 daily 0.8 https://mararating.com/report/fostamatinib-for-treating-refractory-chronic-immune-thrombocytopenia-as-of-october-2022/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/fremanezumab-for-preventing-migraine-as-of-february-2022/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/futibatinib-for-treating-locally-advanced-or-metastatic-cholangiocarcinoma-with-fgfr2-fusion-or-rearrangement-that-has-progressed-after-at-least-one-prior-line-of-systemic-therapy-as-of-september-2024/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/galcanezumab-for-preventing-migraine-as-of-november-2020/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/ganaxolone-for-treating-seizures-caused-by-cdkl5-deficiency-disorder-in-people-2-years-and-over-as-of-february-2025/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/gilteritinib-for-treating-relapsed-or-refractory-acute-myeloid-leukaemia-as-of-august-2020/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/glofitamab-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-2-or-more-systemic-treatments-as-of-october-2023/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/guselkumab-for-treating-active-psoriatic-arthritis-after-inadequate-response-to-dmards-as-of-august-2022/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/ibrutinib-for-treating-waldenstroms-macroglobulinaemia-as-of-june-2022/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/ibrutinib-for-untreated-chronic-lymphocytic-leukaemia-as-of-may-2023/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/icosapent-for-reducing-the-risk-of-cardiovascular-events-in-people-with-raised-triglycerides-as-of-july-2022/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/imlifidase-for-desensitisation-treatment-before-kidney-transplant-in-people-with-chronic-kidney-disease-as-of-july-2022/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/inclisiran-for-treating-primary-hypercholesterolaemia-or-mixed-dyslipidaemia-as-of-october-2021/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/iptacopan-for-treating-paroxysmal-nocturnal-haemoglobinuria-as-of-september-2024/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/isatuximab-for-treating-relapsed-and-refractory-multiple-myeloma-as-of-november-2020/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/ivosidenib-for-treating-advanced-cholangiocarcinoma-with-an-idh1-r132-mutation-after-1-or-more-systemic-treatments-as-of-january-2024/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/ivosidenib-for-untreated-acute-myeloid-leukaemia-with-an-idh1-r132-mutation-as-of-june-2024/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/ixazomib-for-treating-relapsed-or-refractory-multiple-myeloma-as-of-february-2023/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/ixekizumab-for-treating-axial-spondyloarthritis-as-of-july-2021/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/larotrectinib-for-treating-ntrk-fusion-positive-solid-tumours-as-of-may-2020/ 2025-11-27T13:22:47+00:00 daily 0.8 https://mararating.com/report/latanoprostnetarsudil-for-reducing-intraocular-pressure-iop-in-adults-with-primary-open-angle-glaucoma-or-ocular-hypertension-as-of-october-2024/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lebrikizumab-for-treating-moderate-to-severe-atopic-dermatitis-in-people-12-years-and-over-as-of-july-2024/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lenalidomide-for-previously-treated-follicular-lymphoma-grade-1-to-3a-as-of-april-2020/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lenalidomide-for-maintenance-treatment-after-an-autologous-stem-cell-transplant-for-newly-diagnosed-multiple-myeloma-as-of-march-2021/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lenvatinib-for-untreated-advanced-renal-cell-carcinoma-in-adults-as-of-january-2023/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/linzagolix-for-treating-moderate-to-severe-symptoms-of-uterine-fibroids-as-of-august-2024/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/liraglutide-for-managing-overweight-and-obesity-as-of-december-2020/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lisocabtagene-for-treating-relapsed-or-refractory-large-b-cell-lymphoma-after-first-line-chemoimmunotherapy-when-a-stem-cell-transplant-is-suitable-as-of-march-2025/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/loncastuximab-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma-after-2-or-more-systemic-treatments-as-of-january-2024/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lorlatinib-for-treating-anaplastic-lymphoma-kinase-alk-positive-advanced-non-small-cell-lung-cancer-as-of-may-2020/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lorlatinib-for-the-treatment-of-adult-patients-with-anaplastic-lymphoma-kinase-alk-positive-advanced-non-small-cell-lung-cancer-nsclc-previously-not-treated-with-an-alk-inhibitor-as-of-july-2023/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lusutrombopag-for-treating-thrombocytopenia-in-people-with-chronic-liver-disease-needing-a-planned-invasive-procedure-as-of-january-2020/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/lutetium177-for-treating-psma-positive-hormone-relapsed-metastatic-prostate-cancer-after-2-or-more-treatments-as-of-november-2023/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/maribavir-for-treating-refractory-cytomegalovirus-infection-after-transplant-as-of-january-2023/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/mavacamten-for-treating-symptomatic-obstructive-hypertrophic-cardiomyopathy-as-of-september-2023/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/mepolizumab-for-treating-severe-eosinophilic-asthma-as-of-february-2021/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/mexiletine-for-treating-the-symptoms-of-myotonia-in-non-dystrophic-myotonic-disorders-as-of-december-2021/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/midostaurin-for-treating-advanced-systemic-mastocytosis-as-of-september-2021/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/mirikizumab-for-treating-moderately-to-severely-active-ulcerative-colitis-as-of-october-2023/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/mogamulizumab-for-previously-treated-mycosis-fungoides-and-sezary-syndrome-as-of-december-2021/ 2025-11-27T13:22:53+00:00 daily 0.8 https://mararating.com/report/molnupiravir-for-treating-covid-19-as-of-april-2025/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/momelotinib-for-treating-myelofibrosis-related-splenomegaly-or-symptoms-as-of-march-2024/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/mosunetuzumab-for-treating-relapsed-or-refractory-follicular-lymphoma-as-of-may-2023/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/naldemedine-for-treating-opioid-induced-constipation-as-of-september-2020/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/natalizumab-for-the-treatment-of-adults-with-highly-active-relapsing-remitting-multiple-sclerosis-as-of-may-2024/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nintedanib-for-treating-progressive-fibrosing-interstitial-lung-diseases-as-of-november-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nintedanib-for-treating-idiopathic-pulmonary-fibrosis-when-forced-vital-capacity-is-above-80-predicted-as-of-february-2023/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/niraparib-for-maintenance-treatment-of-advanced-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-first-line-platinum-based-chemotherapy-as-of-february-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/niraparib-for-maintenance-treatment-of-relapsed-platinum-sensitive-ovarian-fallopian-tube-and-peritoneal-cancer-as-of-april-2022/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nirmatrelvir-for-treating-covid-19-as-of-may-2025/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-advanced-squamous-non-small-cell-lung-cancer-after-chemotherapy-as-of-october-2020/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-adjuvant-treatment-of-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease-as-of-march-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-treating-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma-after-prior-fluoropyrimidine-and-platinum-based-combination-chemotherapy-as-of-june-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-advanced-non-squamous-non-small-cell-lung-cancer-after-chemotherapy-as-of-july-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-treating-metastatic-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency-as-of-july-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-untreated-metastatic-non-small-cell-lung-cancer-as-of-september-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-treating-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-after-platinum-based-chemotherapy-as-of-october-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-adjuvant-treatment-of-resected-oesophageal-or-gastro-oesophageal-junction-cancer-as-of-november-2021/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-untreated-advanced-renal-cell-carcinoma-as-of-march-2022/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-adjuvant-treatment-of-invasive-urothelial-cancer-at-high-risk-of-recurrence-as-of-august-2022/ 2025-11-27T13:22:59+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-untreated-unresectable-malignant-pleural-mesothelioma-as-of-august-2022/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-untreated-her2-negative-advanced-gastric-gastro-oesophageal-junction-or-oesophageal-adenocarcinoma-as-of-january-2023/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-untreated-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma-as-of-february-2023/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-neoadjuvant-treatment-of-resectable-non-small-cell-lung-cancer-as-of-march-2023/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/nivolumab-for-untreated-unresectable-or-metastatic-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency-as-of-may-2025/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/nivolumabrelatlimab-for-untreated-unresectable-or-metastatic-melanoma-in-people-12-years-and-over-as-of-february-2024/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/obinutuzumab-for-treating-follicular-lymphoma-after-rituximab-as-of-may-2020/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/ofatumumab-for-treating-relapsing-remitting-multiple-sclerosis-as-of-may-2021/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/olaparib-for-adjuvant-treatment-of-brca-mutation-positive-her2-negative-high-risk-early-breast-cancer-after-chemotherapy-as-of-may-2023/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/olaparib-for-treating-hormone-relapsed-metastatic-prostate-cancer-with-brca1-or-brca2-mutations-that-has-progressed-after-a-newer-hormonal-treatment-as-of-may-2023/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/olaparib-for-maintenance-treatment-of-relapsed-platinum-sensitive-ovarian-fallopian-tube-or-peritoneal-cancer-after-2-or-more-courses-of-platinum-based-chemotherapy-as-of-july-2023/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/olaparib-for-maintenance-treatment-of-advanced-high-grade-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer-as-of-january-2024/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/olaparib-for-untreated-hormone-relapsed-metastatic-prostate-cancer-as-of-february-2024/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/olaparib-for-maintenance-treatment-of-brca-mutation-positive-advanced-ovarian-fallopian-tube-or-peritoneal-cancer-after-response-to-first-line-platinum-based-chemotherapy-as-of-march-2024/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/olaparib-for-treating-brca-mutation-positive-her2-negative-advanced-breast-cancer-after-chemotherapy-as-of-february-2025/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/oral-for-maintenance-treatment-of-acute-myeloid-leukaemia-after-induction-therapy-as-of-october-2022/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/osimertinib-for-treating-egfr-t790m-mutation-positive-advanced-non-small-cell-lung-cancer-as-of-october-2020/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/osimertinib-for-untreated-locally-advanced-or-metastatic-egfr-mutation-positive-non-small-cell-lung-cancer-as-of-october-2020/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/osimertinib-for-adjuvant-treatment-of-egfr-mutation-positive-non-small-cell-lung-cancer-after-complete-tumour-resection-as-of-february-2025/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/osimertinib-for-the-first-line-treatment-of-adult-patients-with-advanced-nsclc-whose-tumours-have-egfr-exon-19-deletions-or-exon-21-l858r-substitution-mutations-as-of-may-2025/ 2025-11-27T13:23:05+00:00 daily 0.8 https://mararating.com/report/ozanimod-for-treating-relapsing-remitting-multiple-sclerosis-as-of-june-2021/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/ozanimod-for-treating-moderately-to-severely-active-ulcerative-colitis-as-of-october-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/palbociclib-for-treating-hormone-receptor-positive-her2-negative-advanced-breast-cancer-after-endocrine-therapy-as-of-october-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/palforzia-for-treating-peanut-allergy-in-children-and-young-people-as-of-february-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/patiromer-for-treating-hyperkalaemia-as-of-february-2020/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pegcetacoplan-for-treating-paroxysmal-nocturnal-haemoglobinuria-as-of-march-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/peginterferon-for-treating-relapsing-remitting-multiple-sclerosis-as-of-february-2020/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pegunigalsidase-for-treating-fabry-disease-as-of-october-2023/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-treating-relapsed-or-refractory-classical-hodgkin-lymphoma-as-of-may-2024/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-the-first-line-treatment-of-advanced-renal-cell-carcinoma-rcc-in-adults-as-of-september-2020/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-untreated-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma-as-of-november-2020/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-untreated-metastatic-non-squamous-non-small-cell-lung-cancer-as-of-march-2021/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-treating-locally-advanced-or-metastatic-urothelial-carcinoma-after-platinum-containing-chemotherapy-as-of-april-2021/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-untreated-metastatic-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency-as-of-june-2021/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-untreated-locally-advanced-unresectable-or-metastatic-carcinoma-of-the-oesophagus-in-adults-whose-tumours-express-pd-l1-with-a-cps-of-10-or-more-as-of-august-2024/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-adjuvant-treatment-of-completely-resected-stage-3-melanoma-with-lymph-node-involvement-as-of-february-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-untreated-metastatic-squamous-non-small-cell-lung-cancer-as-of-february-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-treating-relapsed-or-refractory-classical-hodgkin-lymphoma-after-stem-cell-transplant-or-at-least-2-previous-therapies-as-of-february-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-treating-triple-negative-locally-recurrent-unresectable-or-metastatic-breast-cancer-as-of-june-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-adjuvant-treatment-of-renal-cell-carcinoma-at-increased-risk-of-recurrence-as-of-october-2022/ 2025-11-27T13:23:11+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-adjuvant-treatment-of-resected-stage-2b-or-2c-melanoma-as-of-october-2022/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-neoadjuvant-and-adjuvant-treatment-of-triplenegative-early-or-locally-advanced-breast-cancer-as-of-december-2022/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-treating-advanced-or-recurrent-endometrial-cancer-as-of-june-2023/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-previously-treated-endometrial-biliary-colorectal-gastric-or-small-intestine-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency-as-of-september-2023/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-treating-persistent-recurrent-or-metastatic-cervical-cancer-in-adults-whose-tumours-express-pd-l1-with-a-cps-%e2%89%a5-1-as-of-december-2023/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-treating-relapsed-or-refractory-classical-hodgkin-lymphoma-in-people-3-years-and-over-as-of-may-2024/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-the-first-line-treatment-of-locally-advanced-unresectable-or-metastatic-her2-positive-gastric-or-gastro-oesophageal-junction-adenocarcinoma-in-adults-whose-tumours-express-pd-l1-with/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-untreated-advanced-her2-negative-gastric-or-gastro-oesophageal-junction-adenocarcinoma-as-of-august-2024/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-treating-resectable-non-small-cell-lung-cancer-as-of-november-2024/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pembrolizumab-for-adjuvant-treatment-of-resected-non-small-cell-lung-cancer-as-of-february-2025/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pemigatinib-for-treating-relapsed-or-refractory-advanced-cholangiocarcinoma-with-fgfr2-fusion-or-rearrangement-as-of-august-2021/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pitolisant-for-treating-excessive-daytime-sleepiness-caused-by-obstructive-sleep-apnoea-as-of-march-2022/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/polatuzumab-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-as-of-september-2020/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/polatuzumab-for-the-treatment-of-adult-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma-dlbcl-as-of-march-2023/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/ponesimod-for-treating-relapsing-remitting-multiple-sclerosis-as-of-february-2022/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/pralsetinib-for-treating-ret-fusion-positive-advanced-non-small-cell-lung-cancer-as-of-august-2022/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/quizartinib-for-induction-consolidation-and-maintenance-treatment-of-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukaemia-as-of-october-2024/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/ranibizumab-for-the-treatment-of-age-related-macular-degeneration-as-of-may-2024/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/ranibizumab-for-treating-visual-impairment-due-to-diabetic-macular-oedema-as-of-october-2023/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion-as-of-may-2024/ 2025-11-27T13:23:17+00:00 daily 0.8 https://mararating.com/report/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia-as-of-may-2024/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/ravulizumab-for-treating-paroxysmal-nocturnal-haemoglobinuria-as-of-may-2021/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/ravulizumab-for-treating-atypical-haemolytic-uraemic-syndrome-as-of-june-2021/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/regorafenib-for-previously-treated-metastatic-colorectal-cancer-as-of-february-2023/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/relugolix-for-treating-moderate-to-severe-symptoms-of-uterine-fibroids-as-of-october-2022/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/relugolix-for-treating-hormone-sensitive-prostate-cancer-as-of-august-2024/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/relugolix-for-treating-symptoms-of-endometriosis-as-of-april-2025/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/remdesivir-for-treating-covid-19-as-of-may-2024/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/ribociclib-for-treating-hormone-receptor-positive-her2-negative-advanced-breast-cancer-after-endocrine-therapy-as-of-march-2021/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/rimegepant-for-preventing-migraine-as-of-july-2023/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/rimegepant-for-treating-migraine-as-of-october-2023/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/ripretinib-for-treating-advanced-gastrointestinal-stromal-tumour-after-3-or-more-treatments-as-of-may-2023/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/risankizumab-for-treating-active-psoriatic-arthritis-after-inadequate-response-to-dmards-as-of-july-2022/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/risankizumab-for-treating-moderately-to-severely-active-crohns-disease-in-people-16-years-and-over-as-of-may-2023/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/risankizumab-for-treating-moderately-to-severely-active-ulcerative-colitis-as-of-august-2024/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/risdiplam-for-treating-spinal-muscular-atrophy-as-of-december-2023/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/ritlecitinib-for-treating-severe-alopecia-areata-in-people-12-years-and-over-as-of-march-2024/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/rivaroxaban-for-the-prevention-of-stroke-and-systemic-embolism-in-people-with-atrial-fibrillation-as-of-july-2021/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/romosozumab-for-treating-severe-osteoporosis-in-people-after-menopause-who-are-at-high-risk-of-fracture-as-of-may-2022/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/roxadustat-for-treating-symptomatic-anaemia-in-chronic-kidney-disease-as-of-july-2022/ 2025-11-27T13:23:23+00:00 daily 0.8 https://mararating.com/report/rucaparib-for-maintenance-treatment-of-relapsed-platinum-sensitive-ovarian-fallopian-tube-or-peritoneal-cancer-as-of-september-2024/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/rucaparib-for-maintenance-treatment-of-advanced-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-first-line-platinum-based-chemotherapy-as-of-april-2025/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/ruxolitinib-for-treating-polycythaemia-vera-as-of-october-2023/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/ruxolitinib-for-treating-acute-graft-versus-host-disease-that-responds-inadequately-to-corticosteroids-in-people-12-years-and-over-as-of-april-2025/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/sacituzumab-for-treating-unresectable-triple-negative-advanced-breast-cancer-after-2-or-more-therapies-as-of-august-2022/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/sapropterin-for-treating-hyperphenylalaninaemia-in-phenylketonuria-as-of-september-2021/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/secukinumab-for-treating-non-radiographic-axial-spondyloarthritis-as-of-july-2021/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/secukinumab-for-treating-moderate-to-severe-plaque-psoriasis-in-children-and-young-people-as-of-october-2021/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/secukinumab-for-treating-moderate-to-severe-hidradenitis-suppurativa-as-of-december-2023/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/selinexor-for-treating-relapsed-or-refractory-multiple-myeloma-after-4-or-more-treatments-as-of-may-2024/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/selinexor-for-treating-multiple-myeloma-in-adults-as-of-may-2024/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/selpercatinib-for-untreated-ret-fusion-positive-advanced-non-small-cell-lung-cancer-as-of-july-2023/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/selpercatinib-for-advanced-thyroid-cancer-with-ret-alterations-after-treatment-with-a-targeted-cancer-drug-in-people-12-years-and-over-as-of-february-2025/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/selpercatinib-for-advanced-thyroid-cancer-with-ret-alterations-untreated-with-a-targeted-cancer-drug-in-people-12-years-and-over-as-of-february-2025/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/selpercatinib-for-treating-ret-fusion-positive-advanced-non-small-cell-lung-cancer-as-of-february-2025/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/semaglutide-for-managing-overweight-and-obesity-as-of-september-2023/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/siponimod-for-treating-secondary-progressive-multiple-sclerosis-with-active-disease-evidenced-by-relapses-or-imaging-features-of-inflammatory-activity-as-of-november-2020/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/sodium-for-treating-hyperkalaemia-as-of-january-2022/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/solriamfetol-for-treating-excessive-daytime-sleepiness-caused-by-narcolepsy-as-of-january-2022/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/solriamfetol-for-treating-excessive-daytime-sleepiness-caused-by-obstructive-sleep-apnoea-as-of-march-2022/ 2025-11-27T13:23:29+00:00 daily 0.8 https://mararating.com/report/somapacitan-for-treating-growth-hormone-deficiency-in-people-3-to-17-years-as-of-june-2025/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/somatrogon-for-treating-growth-disturbance-in-children-and-young-people-aged-3-years-and-over-as-of-february-2023/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/sotagliflozin-for-treating-type-1-diabetes-as-of-february-2020/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/sotorasib-for-treating-kras-g12c-mutation-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-as-of-march-2022/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tafamidis-for-treating-transthyretin-amyloidosis-with-cardiomyopathy-as-of-june-2024/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tafasitamab-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-as-of-may-2023/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/talazoparib-for-treating-her2-negative-advanced-breast-cancer-with-germline-brca-mutations-as-of-february-2024/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/targetedrelease-for-treating-primary-immunoglobulin-a-nephropathy-as-of-december-2023/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tebentafusp-for-treating-advanced-uveal-melanoma-as-of-january-2025/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/teclistamab-for-treating-relapsed-and-refractory-multiple-myeloma-after-3-or-more-treatments-as-of-november-2024/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/teduglutide-for-treating-short-bowel-syndrome-as-of-june-2022/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tenecteplase-for-treating-acute-ischaemic-stroke-as-of-july-2024/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tepotinib-for-treating-advanced-non-small-cell-lung-cancer-with-metex14-skipping-alterations-as-of-may-2022/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tezepelumab-for-treating-severe-asthma-as-of-april-2023/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tirzepatide-for-treating-type-2-diabetes-as-of-october-2023/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tirzepatide-for-managing-overweight-and-obesity-as-of-december-2024/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tisagenlecleucel-for-treating-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukaemia-in-people-25-years-and-under-as-of-may-2024/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tixagevimab-for-preventing-covid-19-as-of-june-2023/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tofacitinib-for-treating-active-polyarticular-juvenile-idiopathic-arthritis-and-juvenile-psoriatic-arthritis-as-of-october-2021/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/tofacitinib-for-treating-active-ankylosing-spondylitis-as-of-october-2023/ 2025-11-27T13:23:34+00:00 daily 0.8 https://mararating.com/report/trabectedin-for-the-treatment-of-advanced-soft-tissue-sarcoma-as-of-february-2021/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/trastuzumab-for-adjuvant-treatment-of-her2-positive-early-breast-cancer-as-of-june-2020/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/trastuzumab-for-treating-her2-positive-unresectable-or-metastatic-breast-cancer-after-2-or-more-anti-her2-therapies-as-of-may-2021/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/trastuzumab-for-treating-her2-positive-unresectable-or-metastatic-breast-cancer-after-1-or-more-anti-her2-treatments-as-of-february-2023/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/trastuzumab-for-treating-her2-low-metastatic-or-unresectable-breast-cancer-after-chemotherapy-as-of-july-2024/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/treosulfan-for-conditioning-treatment-before-allogeneic-haematopoietic-stem-cell-transplant-as-of-august-2020/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/trifluridinetipiracil-for-treating-metastatic-gastric-cancer-or-gastrooesophageal-junction-adenocarcinoma-after-2-or-more-treatments-as-of-december-2022/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/trifluridinetipiracil-for-treating-metastatic-colorectal-cancer-after-2-systemic-treatments-as-of-september-2024/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/tucatinib-for-treating-her2-positive-locally-advanced-or-metastatic-breast-cancer-after-2-or-more-anti-her2-therapies-as-of-april-2022/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/ublituximab-for-treating-relapsing-forms-of-multiple-sclerosis-as-of-december-2024/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/upadacitinib-for-treating-severe-rheumatoid-arthritis-as-of-december-2020/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/upadacitinib-for-treating-moderate-rheumatoid-arthritis-as-of-november-2021/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/upadacitinib-for-treating-active-psoriatic-arthritis-after-inadequate-response-to-dmards-as-of-february-2022/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/upadacitinib-for-treating-active-ankylosing-spondylitis-as-of-september-2022/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/upadacitinib-for-treating-moderately-to-severely-active-ulcerative-colitis-as-of-january-2023/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/upadacitinib-for-treating-active-non-radiographic-axial-spondyloarthritis-as-of-february-2023/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/upadacitinib-for-treating-moderately-to-severely-active-crohns-disease-as-of-june-2023/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/ustekinumab-for-treating-moderately-to-severely-active-ulcerative-colitis-as-of-june-2020/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/vadadustat-for-treating-symptomatic-anaemia-in-adults-having-dialysis-for-chronic-kidney-disease-as-of-january-2025/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/vamorolone-for-treating-duchenne-muscular-dystrophy-in-people-4-years-and-over-as-of-january-2025/ 2025-11-27T13:23:40+00:00 daily 0.8 https://mararating.com/report/venetoclax-for-untreated-chronic-lymphocytic-leukaemia-as-of-december-2020/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/venetoclax-for-untreated-acute-myeloid-leukaemia-when-intensive-chemotherapy-is-unsuitable-as-of-february-2022/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/venetoclax-for-untreated-acute-myeloid-leukaemia-when-intensive-chemotherapy-is-unsuitable-as-of-april-2022/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/venetoclax-for-treating-chronic-lymphocytic-leukaemia-as-of-june-2022/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/vibegron-for-treating-symptoms-of-overactive-bladder-syndrome-as-of-september-2024/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/voclosporin-for-treating-lupus-nephritis-as-of-may-2023/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/vutrisiran-for-treating-hereditary-transthyretin-related-amyloidosis-as-of-february-2023/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/zanubrutinib-for-treating-waldenstroms-macroglobulinaemia-as-of-october-2022/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/zanubrutinib-for-treating-chronic-lymphocytic-leukaemia-as-of-november-2023/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/zanubrutinib-for-treating-marginal-zone-lymphoma-after-anti-cd20-based-treatment-as-of-september-2024/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/zolbetuximab-for-the-first-line-treatment-of-adult-patients-with-locally-advanced-unresectable-or-metastatic-human-epidermal-growth-factor-receptor-2-her2-negative-gastric-or-gastro-oesophageal-junc/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/aficamten-for-treating-symptomatic-obstructive-hypertrophic-cardiomyopathy-as-of-august-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/brensocatib-for-treating-non-cystic-fibrosis-bronchiectasis-as-of-august-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/cenobamate-for-treating-focal-onset-seizures-in-epilepsy-as-of-july-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/datopotamab-for-the-treatment-of-hr-positive-her2-negative-metastatic-breast-cancer-as-of-august-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/donanemab-for-slowing-cognitive-decline-in-early-alzheimers-disease-as-of-august-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/elexacaftor-for-treating-cystic-fibrosis-as-of-august-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/fruquintinib-for-previously-treated-metastatic-colorectal-cancer-as-of-july-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/lecanemab-for-treating-early-alzheimers-disease-as-of-september-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/nemolizumab-for-treating-moderate-to-severe-atopic-dermatitis-in-people-12-years-and-over-as-of-july-2025/ 2025-11-27T13:23:46+00:00 daily 0.8 https://mararating.com/report/nipocalimab-for-generalized-myasthenia-gravis-as-of-august-2025/ 2025-11-27T13:23:52+00:00 daily 0.8 https://mararating.com/report/suzetrigine-for-treating-neuropathic-pain-as-of-august-2025/ 2025-11-27T13:23:52+00:00 daily 0.8 https://mararating.com/report/mavorixafor-for-severe-chronic-neutropenia-as-of-august-2025/ 2025-11-27T13:23:52+00:00 daily 0.8 https://mararating.com/report/rilzabrutinib-for-the-treatment-of-immune-thrombocytopenia-itp-as-of-september-2025/ 2025-11-27T13:23:52+00:00 daily 0.8 https://mararating.com/report/sotatercept-for-treatment-of-heart-failure-with-preserved-ejection-fraction-complicated-by-combined-pulmonary-hypertension-as-of-november-2025/ 2025-11-27T13:23:52+00:00 daily 0.8 https://mararating.com/with-130m-protego-pushes-forward-a-new-type-of-amyloidosis-drug/ 2025-12-01T13:29:22+00:00 daily 0.8 https://mararating.com/belite-continues-ascent-as-stargardt-drug-hits-mark-in-late-stage-trial/ 2025-12-01T16:02:59+00:00 daily 0.8 https://mararating.com/regeneron-inks-gene-editing-deal-with-startup-tessera/ 2025-12-01T17:29:11+00:00 daily 0.8 https://mararating.com/uk-agrees-to-boost-drug-prices-to-dodge-us-pharma-tariffs/ 2025-12-01T17:32:14+00:00 daily 0.8 https://mararating.com/the-clever-tool-increasingly-getting-bigger-biotech-deals-signed/ 2025-12-02T17:59:23+00:00 daily 0.8